Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes

Atherosclerosis

Volumn 241, Issue 2, 2015, Pages 409-418

  Vallejo Vaz, Antonio J ^a   Kondapally Seshasai, Sreenivasa Rao ^a   Kurogi, Kazumasa ^b   Michishita, Ichiro ^c   Nozue, Tsuyoshi ^c   Sugiyama, Seigo ^d   Tsimikas, Sotirios ^e   Yoshida, Hiroshi ^f   Ray, Kausik K ^g  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Nobeoka Prefectural Hospital   (Japan)

^c Yokohama Sakae Kyosai Hospital   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Diabetes mellitus; Glucose; Glycated haemoglobin; HbA1c; Meta analysis; NK 104; Pitavastatin

Indexed keywords

ATORVASTATIN; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; QUINOLINE DERIVATIVE;

ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; META ANALYSIS; NEW ONSET DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BLOOD; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; DRUG EFFECTS; DYSLIPIDEMIAS; INCIDENCE; METABOLISM; ODDS RATIO; RISK ASSESSMENT; RISK FACTOR;

BIOMARKERS; BLOOD GLUCOSE; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS; DYSLIPIDEMIAS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; ODDS RATIO; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84936817948     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.06.001     Document Type: Article

References (58)

1. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias. Eur. Heart J. 2011, 32:1769-1818. http://dx.doi.org/10.1093/eurheartj/ehr158.
2. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129(25Suppl. 2):S1-S45. http://dx.doi.org/10.1161/01.cir.0000437738.63853.7a.
3. Armitage J. The safety of statins in clinical practice. Lancet 2007, 370(9601):1781-1790. http://dx.doi.org/10.1016/S0140-6736(07)60716-8.
4. Ridker P.M., Pradhan A., MacFadyen J.G., Libby P., Glynn R.J. Cardiovascular benefi ts and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012, 380:565-571. http://dx.doi.org/10.1016/S0140-6736(12)61190-8.
5. Ray K. Statin diabetogenicity: guidance for clinicians. Cardiovasc Diabetol. 2013, 12(Suppl. 1):S3. http://dx.doi.org/10.1186/1475-2840-12-S1-S3.
6. Colbert J.D., Stone J.A. Statin use and the risk of incident diabetes mellitus: a review of the literature. Can. J. Cardiol. 2012, 28:581-589. http://dx.doi.org/10.1016/j.cjca.2012.03.021.
7. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland coronary prevention study. Circulation 2001, 103:357-362. http://dx.doi.org/10.1161/01.CIR.103.3.357.
8. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742. http://dx.doi.org/10.1016/S0140-6736(09)61965-6.
9. Preiss D., Kondapally Seshasai S.R., Welsh P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. A meta-analysis. JAMA 2011, 305(24):2556-2564. http://dx.doi.org/10.1001/jama.2011.860.
10. Waters D.D., Ho J.E., DeMicco D.A., et al. Predictors of new-onset diabetes in patients treated with atorvastatin. Results from 3 large randomized clinical trials. J. Am. Coll. Cardiol. 2011, 57:1535-1545. http://dx.doi.org/10.1016/j.jacc.2010.10.047.
11. U.S. Food and Drug Administration (FDA). http://www.fda.gov/drugs/drugsafety/ucm293101.htm.
12. European Medicines Agency (EMEA), European Union. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/01/WC500120115.pdf.
13. Odawara M., Yamazaki T., Kishimoto J., et al. Effect of pitavastatin on the incidence of diabetes in Japanese individuals with impaired glucose tolerance. Diabetologia 2013, 56(Suppl. 1):S59. http://dx.doi.org/10.1007/s00125-013-3012-z.
14. Terauchi Y., Yamazaki T., Kishimoto J., et al. Differential impact of pitavastatin on the incidence of diabetes in patients with or without hypertension: sub-analysis of J-PREDICT. Diabetes 2014, 63:A272. http://dx.doi.org/10.2337/db14-833-1316.
15. Pitavastatin. Itavastatin, Nisvastatin, Nk 104, Nks 104, P 872441. Drugs R D 2002;3(1):58-60. http://dx.doi.org/10.2165/00126839-200203010-00014.
16. Wensel T.M., Waldrop B.A., Wensel B. Pitavastatin: a new HMG-CoA reductase inhibitor. Ann. Pharmacother. 2010, 44(3):507-514. http://dx.doi.org/10.1345/aph.1M624.
17. Fujino H., Nakai D., Nakagomi R., Saito M., Tokui T., Kojima J. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase. Arzneimittelforschung 2004, 54(7):382-388. http://dx.doi.org/10.1055/s-0031-1296988.
18. ClinicalTrials.gov. U.S. National Institutes of Health. http://https://www.clinicaltrials.gov.
19. European Union Clinical Trials Register. European Medicines Agency. https://www.clinicaltrialsregister.eu.
20. University hospital Medical Information Network (UMIN) Center, Japan. http://www.umin.ac.jp.
21. Introduction to Meta-analysis 2009, John Wiley & Sons, Ltd, Chapters 10-12. M. Borenstein, L.V. Hedges, J.P.T. Higgins, H.R. Rothstein (Eds.).
22. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 2011, The Cochrane Collaboration, [updated March 2011]. http://www.cochrane-handbook.org, J.P.T. Higgins, S. Green (Eds.).
23. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21(11):1539-1558. http://dx.doi.org/10.1002/sim.1186.
24. Egger M., Smith G.D., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634. http://dx.doi.org/10.1136/bmj.315.7109.629.
25. Harbord R.M., Egger M., Sterne J.A. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat. Med. 2006, 25:3443-3457. http://dx.doi.org/10.1002/sim.2380.
26. Ikeda K., Takahashi T., Yamada H., et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). Eur. J. Prev. Cardiol. 2013, 20(6):1069-1079. http://dx.doi.org/10.1177/2047487312451539.
27. Eriksson M., Budinski D., Hounslow N. Long-term efficacy of pitavastatin versus simvastatin. Adv. Ther. 2011, 28(9):799-810. http://dx.doi.org/10.1007/s12325-011-0057-6.
28. Cai R., Yuan Y., Zhou Y., et al. Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis. PLoS One 2014, 9(8):e104922. http://dx.doi.org/10.1371/journal.pone.0104922.
29. Mills E.J., Wu P., Chong G., et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011, 104(2):109-124. http://dx.doi.org/10.1093/qjmed/hcq165.
30. Navarese E.P., Buffon A., Andreotti F., et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am. J. Cardiol. 2013, 111:1123-1130. http://dx.doi.org/10.1016/j.amjcard.2012.12.037.
31. Culver A.L., Ockene I.S., Balasubramanian R., et al. Statin use and risk of diabetes mellitus in postmenopausal women in the women's health initiative. Arch. Intern Med. 2012, 172(2):144-152. http://dx.doi.org/10.1001/archinternmed.2011.625.
32. Keech A., Colquhoun D., Best J., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Results from the lipid trial. Diabetes Care 2003, 26:2713-2721. http://dx.doi.org/10.2337/diacare.26.10.2713.
33. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 2007, 357(22):2248-2261. http://dx.doi.org/10.1056/NEJMoa0706201.
34. Baker W.L., Talati R., White C.M., Coleman C.I. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res. Clin. Pract. 2010, 87(1):98-107. http://dx.doi.org/10.1016/j.diabres.2009.10.008.
35. Chapman M.J., Hounslow N., Orsoni A., et al. Neutral effect of pitavastatin on glycaemic parameters in metabolic syndrome: the CAPITAIN trial. 81st European Atherosclerosis Society Congress, June 2013, Abstract No. 1616.
36. Yokote K., Saito Y. CHIBA study investigators. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). J. Atheroscler. Thromb. 2009, 16(3):297-298. http://doi.org/10.5551/jat.E1008.
37. Kryzhanovski V., Morgan R., Sponseller C., et al. Pitavastatin 4mg provides significantly greater reduction in LDL-C compared to pravastatin 40mg with neutral effects on glucose metabolism: prespecified safety analysis from the short-term Phase-4 PREVAIL-US trial in patients with primary hyperlipidemia or mixed dyslipidemia. J. Am. Coll. Cardiol. 2012, 59(Suppl. 13):E1692. http://doi.org/10.1016/S0735-1097(12)61693-3.
38. Swerdlow D.I., Preiss D., Kuchenbaecker K.B., et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015, 385(9965):351-361. http://dx.doi.org/10.1016/S0140-6736(14)61183-1.
39. Arnaboldi L., Corsini A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler. Suppl. 2015, 16:1-27. http://doi.org/10.1016/S1567-5688(14)70002-9.
40. Drew B.G., Rye K.A., Duffy S.J., et al. The emerging role of HDL in glucose metabolism. Nat. Rev. Endocrinol. 2012, 8(4):237-245. http://doi.org/10.1038/nrendo.2011.235.
41. Meikle P.J., Wong G., Barlow C.K., et al. Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes. PLoS One 2013, 8(9):e74341. http://doi.org/10.1371/journal.pone.0074341.
42. Meikle P.J., Wong G., Tan A.R., et al. New insights into statin action on the dyslipidemia of metabolic syndrome: normalisation of bioactive plasmalogens and sphingolipids in HDL. 81st European Atherosclerosis Society Congress, June 2013, Abstract No. 1643.
43. Meikle P.J., Wonga G., Tan R., et al. New insights into statin action on the dyslipidemia of type 2 diabetes: normalisation of the plasma lipid profile. Atherosclerosis 2014, 235(2):e106-e107. http://doi.org/10.1016/j.atherosclerosis.2014.05.287.
44. Brault M., Ray J., Gomez Y.H., et al. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 2014, 63(6):735-745. http://doi.org/10.1016/j.metabol.2014.02.014.
45. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366(9493):1267-1278. http://dx.doi.org/10.1016/S0140-6736(05)67394-1.
46. Mills E.J., Rachlis B., Wu P., Devereaux P.J., Arora P., Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J. Am. Coll. Cardiol. 2008, 52(22):1769-1781. http://dx.doi.org/10.1016/j.jacc.2008.08.039.
47. Brugts J.J., Yetgin T., Hoeks S.E., et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009, 338:b2376. http://dx.doi.org/10.1136/bmj.b2376.
48. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376(9753):1670-1681. http://dx.doi.org/10.1016/S0140-6736(10)61350-5.
49. Saito Y., Yamada N., Teramoto T., et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002, 162:373-379. http://dx.doi.org/10.1016/S0021-9150(01)00712-2.
50. Budinski D., Arneson V., Hounslow N., Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin. Lipidol. 2009, 4(3):291-302. http://dx.doi.org/10.2217/clp.09.20.
51. Ose L., Budinski D., Hounslow N., Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr. Med. Res. Opin. 2009, 25(11):2755-2764. http://dx.doi.org/10.1185/03007990903290886.
52. Eriksson M., Budinski D., Hounslow N. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Adv. Ther. 2011, 28(9):811-823. http://dx.doi.org/10.1007/s12325-011-0056-7.
53. Stender S., Budinski D., Gosho M., Hounslow N. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur. J. Prev. Cardiol. 2013, 20(1):40-53. http://dx.doi.org/10.1177/2047487312451251.
54. Liu P.Y., Lin L.Y., Lin H.J., et al. Pitavastatin and atorvastatin double-blind randomized comparative study among high-risk patients, including those with type 2 diabetes mellitus, in Taiwan (PAPAGO-T study). PLoS One 2013, 8(10):e76298. http://dx.doi.org/10.1371/journal.pone.0076298.
55. Nozue T., Yamamoto S., Tohyama S., et al. Comparison of arterial remodeling and changes in plaque composition between patients with progression versus regression of coronary atherosclerosis during statin therapy (from the TRUTH study). Am. J. Cardiol. 2012, 109:1247-1253. http://dx.doi.org/10.1016/j.amjcard.2011.12.016.
56. Kurogi K., Sugiyama S., Sakamoto K., et al. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study. J. Cardiol. 2013, 62:87-94. http://dx.doi.org/10.1016/j.jjcc.2013.03.008.
57. Yoshida H., Shoda T., Yanai H., et al. Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. Atherosclerosis 2013, 226:161-164. http://dx.doi.org/10.1016/j.atherosclerosis.2012.10.069.
58. Sponseller C.A., Morgan R.E., Kryzhanovski V.A., Campbell S.E., Davidson M.H. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin. Ther. 2014, 36(8):1211-1222. http://dx.doi.org/10.1016/j.clinthera.2014.06.009.